BEAM
BEAM
NASDAQ · Biotechnology

Beam Therapeutics Inc

$34.14
+1.66 (+5.11%)
As of Jun 21, 9:59 PM ET ·
Financial Highlights (FY 2026)
Revenue
145.36M
Net Income
-83,208,701
Gross Margin
Profit Margin
-57.2%
Rev Growth
+31.9%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.9% 48.9%
Operating Margin -274.6% -247.1% -6.1% -6.1%
Profit Margin -57.2% -54.4% -9.9% -9.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 145.36M 110.22M 476.44M 432.89M
Gross Profit 233.13M 211.83M
Operating Income -399,109,542 -272,367,749 -29,234,950 -26,348,592
Net Income -83,208,701 -56,784,827 -46,993,180 -41,441,136
Gross Margin 48.9% 48.9%
Operating Margin -274.6% -247.1% -6.1% -6.1%
Profit Margin -57.2% -54.4% -9.9% -9.6%
Rev Growth +31.9% +31.9% -6.6% +15.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 420.07M 396.17M
Total Equity 1.92B 2.06B
D/E Ratio 0.22 0.19
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -375,920,619 -270,795,107 -41,088,618 -32,500,848
Free Cash Flow -33,034,013 -43,893,077